Equities

CogState Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
COGZF:QXE

CogState Ltd

Actions
  • Price (USD)1.51
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change+105.74%
  • Beta0.4851
Data delayed at least 15 minutes, as of Feb 06 2026 14:56 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.

  • Revenue in AUD (TTM)74.90m
  • Net income in AUD14.31m
  • Incorporated1999
  • Employees61.00
  • Location
    CogState LtdLevel 32, 367 Collins StreetMELBOURNE 3000AustraliaAUS
  • Phone+61 39664-1300
  • Fax+61 39664-1301
  • Websitehttps://cogstate.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.